- Home
- OCGN
OCGN
Ocugen Inc.
as 02-21-2025 4:00pm EST
Ocugen Inc company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve health and offer hope for patients across the globe. The company's pipeline includes Modifier Gene Therapy Platform, Novel Biologic Therapy for Retinal Diseases, Regenerative Medicine Cell Therapy Platform. The company is developing a modifier gene therapy platform designed to fulfill unmet medical needs related to retinal diseases, including inherited retinal diseases ("IRDs"), such as RP, LCA, Stargardt disease, and multifactorial diseases such as dAMD and Geographic Atrophy ("GA").
| Founded: | 2013 | Country: | United States |
| Employees: | N/A | City: | MALVERN |
| Market Cap: | 229.2M | IPO Year: | N/A |
| Target Price: | $6.00 | AVG Volume (30 days): | 3.4M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 3 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.20 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.64 - $2.10 | Next Earning Date: | 03-05-2025 |
| Revenue: | $4,700,000 | Revenue Growth: | -33.94% |
| Revenue Growth (this year): | -38.82% | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Ocugen Inc. (OCGN)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Fernandes Prabhavathi | OCGN | Director | Nov 26 '24 | Buy | $0.91 | 10,000 | $9,095.00 | 10,000 |
Latest Ocugen Inc. News
OCGN Breaking Stock News: Dive into OCGN Ticker-Specific Updates for Smart Investing
GlobeNewswire
a day ago
Ocugen to Host Conference Call on Wednesday, March 5, 2025 at 8:30 A.M. ET to Discuss Business Updates and Fourth Quarter and Full Year 2024 Financial Results
Insider Monkey
9 days ago
Why Ocugen (OCGN) Is Advancing Today
GlobeNewswire
10 days ago
Ocugen, Inc. Announces Dosing Completion in the Phase 2 ArMaDa Clinical Trial for OCU410—a Multifunctional Modifier Gene Therapy for the Treatment of Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration
MT Newswires
19 days ago
Ocugen Says EMA Panel Issues Positive Opinion for Potential Eye Disease Treatment
GlobeNewswire
19 days ago
Ocugen Announces Positive Opinion of European Medicines Agency’s Committee for Advanced Therapies for Advanced Therapy Medicinal Product Classification for Modifier Gene Therapy Candidate OCU400 for Retinitis Pigmentosa
MT Newswires
22 days ago
Ocugen Files Secondary Stock Shelf
GlobeNewswire
a month ago
Ocugen, Inc. Announces Investigational New Drug Application in Effect After Review by FDA to Initiate Phase 1 Clinical Trial Evaluating First-in-Class OCU500 Inhaled Vaccine Candidate for COVID-19
Clinical Trials Arena
a month ago
Ocugen doses first subject in Phase I trial of diabetic macular oedema treatment
Compare OCGN vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "OCGN Ocugen Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.